QTTB · Insider Trading
Q32 Bio Inc. Common Stock
Every open-market purchase and sale reported by QTTB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Shelia M. Violette | Chief Scientific Officer | Sell | — | — |
| 2026-08-27 | Lee Kalowski | CFO and President | Sell | — | — |
| 2026-08-27 | Jodie Pope Morrison | CEO | Sell | — | — |
| 2026-07-21 | Mark T Iwicki | Director | A | — | — |
| 2026-07-21 | Isaac Manke | Director | A | — | — |
| 2026-07-21 | Sven Ante Lundberg | Director | A | — | — |
| 2026-07-21 | ARTHUR TZIANABOS | Director | A | — | — |
| 2026-07-21 | DAVID S. GRAYZEL | Director | A | — | — |
| 2026-07-21 | Mary Thistle | Director | A | — | — |
| 2026-07-21 | KATHLEEN LAPORTE | Director | A | — | — |
| 2026-07-21 | Diyong Xu | Director | A | — | — |
| 2026-07-20 | Jodie Pope Morrison | CEO | A | — | — |
| 2026-07-20 | Shelia M. Violette | Chief Scientific Officer | A | — | — |
| 2026-07-20 | Lee Kalowski | CFO and President | A | — | — |
| 2026-07-02 | Isaac Manke | Director | M | — | — |
| 2026-06-16 | KATHLEEN LAPORTE | Director | A | — | — |
| 2026-06-16 | Mark T Iwicki | Director | A | — | — |
| 2026-06-16 | DAVID S. GRAYZEL | Director | A | — | — |
| 2026-06-16 | Mary Thistle | Director | A | — | — |
| 2026-06-16 | ARTHUR TZIANABOS | Director | A | — | — |
| 2026-06-16 | Isaac Manke | Director | A | — | — |
| 2026-06-16 | Diyong Xu | Director | A | — | — |
| 2026-06-16 | Sven Ante Lundberg | Director | A | — | — |
| 2026-06-01 | OrbiMed Genesis GP LLC | Director | Buy | — | — |
| 2026-06-01 | Diyong Xu | Director | Buy | — | — |
| 2026-03-20 | Jodie Pope Morrison | CEO | A | — | — |
| 2026-03-20 | Lee Kalowski | CFO and President | A | — | — |
| 2026-03-20 | Shelia M. Violette | Chief Scientific Officer | A | — | — |
| 2026-02-27 | Jodie Pope Morrison | CEO | Sell | — | — |
| 2026-02-27 | Lee Kalowski | CFO and President | Sell | — | — |
| 2026-02-27 | Shelia M. Violette | Chief Scientific Officer | Sell | — | — |
| 2026-01-30 | Sven Ante Lundberg | Director | A | — | — |
| 2026-01-30 | DAVID S. GRAYZEL | Director | A | — | — |
| 2026-01-30 | KATHLEEN LAPORTE | Director | A | — | — |
| 2025-12-04 | Jodie Pope Morrison | CEO | Sell | — | — |
| 2025-12-04 | Lee Kalowski | CFO and President | Sell | — | — |
| 2025-10-27 | ARTHUR TZIANABOS | Director | A | — | — |
| 2025-10-27 | Mark T Iwicki | Director | A | — | — |
| 2025-10-27 | Sven Ante Lundberg | Director | A | — | — |
| 2025-10-27 | KATHLEEN LAPORTE | Director | A | — | — |
| 2025-10-27 | Mary Thistle | Director | A | — | — |
| 2025-10-27 | Diyong Xu | Director | A | — | — |
| 2025-10-27 | DAVID S. GRAYZEL | Director | A | — | — |
| 2025-10-27 | Isaac Manke | Director | A | — | — |
| 2025-08-28 | Shelia M. Violette | Chief Scientific Officer | Sell | — | — |
| 2025-08-28 | Lee Kalowski | CFO and President | Sell | — | — |
| 2025-08-28 | Jodie Pope Morrison | CEO | Sell | — | — |
| 2025-02-27 | Lee Kalowski | CFO and President | A | — | — |
| 2025-02-27 | ARTHUR TZIANABOS | Director | MIXED | — | — |
| 2025-02-27 | KATHLEEN LAPORTE | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 625,000 | — |
| — | Director | 625,000 | — |
| — | CEO | 343,259 | — |
| — | Chief Scientific Officer | 164,048 | — |
| — | CFO and President | 138,471 | — |
| — | Director | 53,521 | — |
| — | Chief Medical Officer | 37,500 | — |
| — | Director | 7,983 | — |
| — | See Remarks | 2,596 | — |
| — | See Remarks | 927 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QTTB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.